1. Home
  2. OKTA vs ILMN Comparison

OKTA vs ILMN Comparison

Compare OKTA & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Okta Inc.

OKTA

Okta Inc.

HOLD

Current Price

$85.82

Market Cap

15.2B

Sector

Technology

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$128.90

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OKTA
ILMN
Founded
2009
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.2B
18.9B
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
OKTA
ILMN
Price
$85.82
$128.90
Analyst Decision
Buy
Hold
Analyst Count
39
15
Target Price
$116.22
$114.93
AVG Volume (30 Days)
2.9M
1.5M
Earning Date
12-02-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.08
4.46
Revenue
$2,840,000,000.00
$4,288,000,000.00
Revenue This Year
$12.76
N/A
Revenue Next Year
$9.34
$2.08
P/E Ratio
$79.89
$28.91
Revenue Growth
12.12
N/A
52 Week Low
$75.05
$68.70
52 Week High
$127.57
$153.06

Technical Indicators

Market Signals
Indicator
OKTA
ILMN
Relative Strength Index (RSI) 55.88 66.70
Support Level $75.05 $124.27
Resistance Level $88.02 $129.72
Average True Range (ATR) 2.97 3.90
MACD 0.91 -0.41
Stochastic Oscillator 83.04 77.82

Price Performance

Historical Comparison
OKTA
ILMN

About OKTA Okta Inc.

Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: